ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-30M11034
Home | Market Reports | Health| Health Conditions
Global Idiopathic Pulmonary Fibrosis IPF Drug Market Research Report 2022
BUY CHAPTERS

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Research Report 2025

Code: QYRE-Auto-30M11034
Report
January 2025
Pages:74
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche Holding AG
Boehringer Ingelheim International GmbH

Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size

The global market for Idiopathic Pulmonary Fibrosis (IPF) Drug was valued at US$ 293 million in the year 2024 and is projected to reach a revised size of US$ 389 million by 2031, growing at a CAGR of 4.2% during the forecast period.

Idiopathic Pulmonary Fibrosis (IPF) Drug Market

Idiopathic Pulmonary Fibrosis (IPF) Drug Market

These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Idiopathic Pulmonary Fibrosis (IPF) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Idiopathic Pulmonary Fibrosis (IPF) Drug.
The Idiopathic Pulmonary Fibrosis (IPF) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Idiopathic Pulmonary Fibrosis (IPF) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Idiopathic Pulmonary Fibrosis (IPF) Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Idiopathic Pulmonary Fibrosis (IPF) Drug Market Report

Report Metric Details
Report Name Idiopathic Pulmonary Fibrosis (IPF) Drug Market
Accounted market size in year US$ 293 million
Forecasted market size in 2031 US$ 389 million
CAGR 4.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Nintedanib
  • Pirfenidone
Segment by Application
  • Hospital
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche Holding AG, Boehringer Ingelheim International GmbH
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Idiopathic Pulmonary Fibrosis (IPF) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Idiopathic Pulmonary Fibrosis (IPF) Drug Market growing?

Ans: The Idiopathic Pulmonary Fibrosis (IPF) Drug Market witnessing a CAGR of 4.2% during the forecast period 2025-2031.

What is the Idiopathic Pulmonary Fibrosis (IPF) Drug Market size in 2031?

Ans: The Idiopathic Pulmonary Fibrosis (IPF) Drug Market size in 2031 will be US$ 389 million.

Who are the main players in the Idiopathic Pulmonary Fibrosis (IPF) Drug Market report?

Ans: The main players in the Idiopathic Pulmonary Fibrosis (IPF) Drug Market are Roche Holding AG, Boehringer Ingelheim International GmbH

What are the Application segmentation covered in the Idiopathic Pulmonary Fibrosis (IPF) Drug Market report?

Ans: The Applications covered in the Idiopathic Pulmonary Fibrosis (IPF) Drug Market report are Hospital, Clinics, Others

What are the Type segmentation covered in the Idiopathic Pulmonary Fibrosis (IPF) Drug Market report?

Ans: The Types covered in the Idiopathic Pulmonary Fibrosis (IPF) Drug Market report are Nintedanib, Pirfenidone

Recommended Reports

Pulmonary Drugs

Fibrosis and Related

Respiratory Disorders

1 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Overview
1.1 Product Definition
1.2 Idiopathic Pulmonary Fibrosis (IPF) Drug by Type
1.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Nintedanib
1.2.3 Pirfenidone
1.3 Idiopathic Pulmonary Fibrosis (IPF) Drug by Application
1.3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size Estimates and Forecasts
1.4.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue 2020-2031
1.4.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales 2020-2031
1.4.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Competition by Manufacturers
2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Idiopathic Pulmonary Fibrosis (IPF) Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug, Product Type & Application
2.7 Global Key Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug, Date of Enter into This Industry
2.8 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Competitive Situation and Trends
2.8.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Idiopathic Pulmonary Fibrosis (IPF) Drug Players Market Share by Revenue
2.8.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Scenario by Region
3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region: 2020-2031
3.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region: 2020-2025
3.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region: 2026-2031
3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region: 2020-2031
3.3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region: 2020-2025
3.3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region: 2026-2031
3.4 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Market Facts & Figures by Country
3.4.1 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2020-2031)
3.4.3 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Market Facts & Figures by Country
3.5.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2020-2031)
3.5.3 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Market Facts & Figures by Country
3.7.1 Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2020-2031)
3.7.3 Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type (2020-2031)
4.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type (2020-2025)
4.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type (2026-2031)
4.1.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2020-2031)
4.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Type (2020-2031)
4.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Type (2020-2025)
4.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Type (2026-2031)
4.2.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Type (2020-2031)
4.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application (2020-2031)
5.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application (2020-2025)
5.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application (2026-2031)
5.1.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Application (2020-2031)
5.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Application (2020-2031)
5.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Application (2020-2025)
5.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Application (2026-2031)
5.2.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Application (2020-2031)
5.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Roche Holding AG
6.1.1 Roche Holding AG Company Information
6.1.2 Roche Holding AG Description and Business Overview
6.1.3 Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolio
6.1.5 Roche Holding AG Recent Developments/Updates
6.2 Boehringer Ingelheim International GmbH
6.2.1 Boehringer Ingelheim International GmbH Company Information
6.2.2 Boehringer Ingelheim International GmbH Description and Business Overview
6.2.3 Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolio
6.2.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Chain Analysis
7.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Production Mode & Process Analysis
7.4 Idiopathic Pulmonary Fibrosis (IPF) Drug Sales and Marketing
7.4.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Channels
7.4.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Distributors
7.5 Idiopathic Pulmonary Fibrosis (IPF) Drug Customer Analysis
8 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Dynamics
8.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Trends
8.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers
8.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Challenges
8.4 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Roche Holding AG
Boehringer Ingelheim International GmbH
List of Tables
 Table 1. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Idiopathic Pulmonary Fibrosis (IPF) Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Idiopathic Pulmonary Fibrosis (IPF) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis (IPF) Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region (2020-2025) & (K Units)
 Table 18. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region (2026-2031) & (K Units)
 Table 20. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2020-2025) & (K Units)
 Table 27. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2026-2031) & (K Units)
 Table 28. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units) by Type (2020-2025)
 Table 51. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units) by Type (2026-2031)
 Table 52. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units) by Application (2020-2025)
 Table 61. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units) by Application (2026-2031)
 Table 62. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price (US$/Unit) by Application (2026-2031)
 Table 70. Roche Holding AG Company Information
 Table 71. Roche Holding AG Description and Business Overview
 Table 72. Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Product
 Table 74. Roche Holding AG Recent Developments/Updates
 Table 75. Boehringer Ingelheim International GmbH Company Information
 Table 76. Boehringer Ingelheim International GmbH Description and Business Overview
 Table 77. Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Product
 Table 79. Boehringer Ingelheim International GmbH Recent Developments/Updates
 Table 80. Key Raw Materials Lists
 Table 81. Raw Materials Key Suppliers Lists
 Table 82. Idiopathic Pulmonary Fibrosis (IPF) Drug Distributors List
 Table 83. Idiopathic Pulmonary Fibrosis (IPF) Drug Customers List
 Table 84. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Trends
 Table 85. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers
 Table 86. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Challenges
 Table 87. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Restraints
 Table 88. Research Programs/Design for This Report
 Table 89. Key Data Information from Secondary Sources
 Table 90. Key Data Information from Primary Sources
 Table 91. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Idiopathic Pulmonary Fibrosis (IPF) Drug
 Figure 2. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Share by Type: 2024 & 2031
 Figure 4. Nintedanib Product Picture
 Figure 5. Pirfenidone Product Picture
 Figure 6. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Clinics
 Figure 10. Others
 Figure 11. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (2020-2031) & (K Units)
 Figure 14. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price (US$/Unit) & (2020-2031)
 Figure 15. Idiopathic Pulmonary Fibrosis (IPF) Drug Report Years Considered
 Figure 16. Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Share by Manufacturers in 2024
 Figure 17. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Idiopathic Pulmonary Fibrosis (IPF) Drug Players: Market Share by Revenue in Idiopathic Pulmonary Fibrosis (IPF) Drug in 2024
 Figure 19. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country (2020-2031)
 Figure 22. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country (2020-2031)
 Figure 23. United States Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country (2020-2031)
 Figure 26. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Region (2020-2031)
 Figure 34. China Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Idiopathic Pulmonary Fibrosis (IPF) Drug by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Idiopathic Pulmonary Fibrosis (IPF) Drug by Type (2020-2031)
 Figure 55. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Idiopathic Pulmonary Fibrosis (IPF) Drug by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Idiopathic Pulmonary Fibrosis (IPF) Drug by Application (2020-2031)
 Figure 58. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price (US$/Unit) by Application (2020-2031)
 Figure 59. Idiopathic Pulmonary Fibrosis (IPF) Drug Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Pirfenidone Drugs Market Research Report 2024
Global Idiopathic Pulmonary Fibrosis Drug Market Research Report 2025
Global Icotinib API Market Research Report 2024
Global Pirfenidone Market Research Report 2024
Global Antifibrotic Drug Market Research Report 2024
Global Pirfenidone Tablets Market Research Report 2024
Global Idiopathic Pulmonary Fibrosis Management Market Research Report 2024
Global Nintedanib Generics Market Research Report 2024
Idiopathic Pulmonary Fibrosis Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Idiopathic Pulmonary Fibrosis IPF Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Interstitial Lung Disease ILD Market Research Report 2024
Pulmonary Fibrosis Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ambrisentantable Market Research Report 2024
Global Antifibrotic Drugs Market Insights Forecast to 2030
Global Anti Fibrotic Therapy for Ocular Fibrosis Market Insights Forecast to 2030
Global Interstitial Pneumonia Market Research Report 2024
Idiopathic Pulmonary Fibrosis Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Osimertinib Generics Market Research Report 2024
Global Nintedanib API Market Research Report 2025
Global Ambrisentan Drug Market Insights Forecast to 2030

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19Z7671
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10V14317
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10O5919
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4I19963
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions